Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
KYMR
KYMR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KYMR News
Kymera Stock Soars as Secretive Hedge Fund Acquires $172 Million Stake.
Dec 14 2025
Barron's
S&P 500 Futures Decline in Pre-Market Session; Fermi and Broadcom Underperform
Dec 12 2025
Barron's
Kymera Receives FDA Fast Track Designation for KT-621, Aiming to Transform Atopic Dermatitis Treatment
Dec 11 2025
Globenewswire
Kymera Receives FDA Fast Track Designation for KT-621, Aiming to Improve Atopic Dermatitis Treatment
Dec 11 2025
Newsfilter
Kymera's oral candidate KT-621 for eczema receives Fast Track designation.
Dec 11 2025
SeekingAlpha
Kymera Therapeutics Prices $602 Million Public Offering of Common Stock
Dec 10 2025
Globenewswire
Kymera Therapeutics Prices $602 Million Public Offering of Common Stock
Dec 10 2025
Newsfilter
Broadcom Set for Approximately 10% Surge? Check Out 10 Leading Analyst Predictions for Tuesday
Dec 09 2025
Benzinga
Kymera Therapeutics Launches $500 Million Public Offering
Dec 08 2025
Globenewswire
Stocks Decline Amid Increasing Bond Yields
Dec 08 2025
NASDAQ.COM
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Stocks Show Varied Performance Amid Rising Bond Yields
Dec 08 2025
NASDAQ.COM
Kymera Reports Encouraging Phase 1b Results for Oral STAT6 Degrader KT-621 in Atopic Dermatitis
Dec 08 2025
NASDAQ.COM
Kymera Shares Reach 52-Week Peak Following Breakthrough Pill for Eczema Treatment
Dec 08 2025
Benzinga
Market Update: Health Care Stocks Gain Ahead of Monday's Opening Bell
Dec 08 2025
Yahoo Finance
Kymera Therapeutics Shares Surge as Investors Show Enthusiasm for Its Anti-Inflammatory Treatment.
Dec 08 2025
Barron's
Show More News
